Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

JAMA oncology - 1 Jan 2016

Gao Shanwu, Tibiche Chabane, Zou Jinfeng, Zaman Naif, Trifiro Mark, O'Connor-McCourt Maureen, Wang Edwin

Abstract excerpt

IMPORTANCE: Decisions regarding adjuvant therapy in patients with stage II colorectal cancer (CRC) have been among the most challenging and controversial in oncology over the past 20 years. OBJECTIVE: To develop robust combinatory cancer hallmark-based gene signature sets (CSS sets) that more accurately predict prognosis and identify a subset of patients with stage II CRC who could gain survival benefits from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Disease-Free Survival

Share to Fluorouracil

Share to Neoplasm Recurrence, Local

Share to Patient Selection

Share to Precision Medicine

Source

Identifiers

PMID: 26502222
DOI: 10.1001/jamaoncol.2015.3413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.PMID 26502222Read ↗

Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.Semantic proximity Read ↗

A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancerSemantic proximity Read ↗

Machine learning-based analysis identifies a 13-gene prognostic signature to improve the clinical outcomes of colorectal cancerSemantic proximity Read ↗

Development and Validation of an 8-Gene Signature to Improve Survival Prediction of Colorectal CancerSemantic proximity Read ↗

Molecular profiling of risk factors for relapse in Japanese patients with stage II colorectal cancer: a retrospective cohort study.Semantic proximity Read ↗

Recurrence‐associated gene signature optimizes recurrence‐free survival prediction of colorectal cancerSemantic proximity Read ↗

A network‐based predictive gene expression signature for recurrence risks in stage II colorectal cancerSemantic proximity Read ↗

12-Gene Signature for Prediction of Chemotherapy Response in Gastric CancerSemantic proximity Read ↗

Improving the overall survival prognosis prediction accuracy: A 9‐gene signature in CRC patientsSemantic proximity Read ↗

CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancerSemantic proximity Read ↗

A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sourcesSemantic proximity Read ↗

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.